KLINIQ: 100 new beauty clinics and gigantic sales growth!

KLINIQ: 100 new beauty clinics and gigantic sales growth!

The Clinic Public Company Limited, better known as KLINIQ, has been making waves in the beauty world in Thailand lately. On November 7, 2025, the Company completed the transition from the MAI exchange to the main exchange of the Stock Exchange of Thailand (SET). This step, how share2trade.com reported, is intended to create the basis for a broader investor base, especially for institutional investors.

KLINIQ’s expansion plans are already in full swing. The company plans to open 100 branches by 2028 to address diverse customer groups. The main brand, KLINIQUE, is aimed at customers with higher purchasing power, while the L.A.B.X brand is primarily aimed at a younger clientele. CEO Dr. Apiruj Thongwat emphasizes that the focus is on developing new markets both locally and internationally.

From a financial perspective, things are going well for KLINIQ. In 2022, the company had sales of 1,647.20 million baht. This rose to 2,318.35 million baht in 2023 and reached 3,008.95 million baht in 2024. This represents a whopping 82.67% sales growth in just two years. Net profit follows this trend, growing from 205.49 million baht in 2022 to 322.19 million baht in 2024. The company continues to target an annual sales increase of 20-25% and is targeting total sales of over 5,000 million baht by 2028.

Market development in aesthetic medicine

Aesthetic medicine is also flourishing in Thailand. The market was valued at approximately USD 1.46 billion in 2023 and is expected to grow at an annual growth rate (CAGR) of 11.6% through 2030. A significant aspect of this development is the increase in medical tourism, with approximately 33.2% of patients from abroad coming to Thailand for these treatments - an aspect favored by the lower costs compared to Western countries. According to the report by grandviewresearch.com, the invasive procedures are dominating the market and the growing interest in minimally invasive procedures is further increasing the demand.

With an increasing number of clinics and specialists offering high quality aesthetic procedures, KLINIQ is positioning itself as a key player in the Thai beauty sector. Innovative products and services are the key to remaining at the forefront of the competition in the coming years.

The company is also strengthened by a well-thought-out dividend policy: KLINIQ plans to continue paying dividends twice a year, which have grown consistently in recent years. The latest distribution of 0.70 baht per share for the first half of 2025 shows that KLINIQ also acts prudently in financial matters.

Overall, the development of KLINIQ and the Thai market for aesthetic medicine shows that there are interesting prospects for both providers and investors - and with a clear focus on growth.